Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative biologic medicines and vaccines. Global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks.
Over the past three decades, biotechnology has changed the face of modern medicine and our ability to treat, manage and prevent a wide variety of diseases – from cancer to autoimmune disorders – with recombinant protein therapeutics. Nearly 70% of all recombinant protein therapeutics marketed today are manufactured in Chinese hamster ovary (CHO) cells. Today, scientists and doctors are addressing complicated and intractable diseases by developing complex protein therapeutics such as bi- and tri-specific proteins, DARPins, triabodies, novel scaffolds decorated with peptides, enzymes and growth factors, etc. While this can be great news for patients, these non-natural scaffolds are often difficult to express in CHO cells at commercially viable levels.
The pressures on the CHO expression system to express these novel and complex proteins led Selexis to develop a series of new modules for its technology platform that address issues such as transcription, translation, glycosylation, folding and secretion bottlenecks. These modules allow the identification of lead candidate clones that will ultimately be used for biologics manufacturing. To mitigate the risks associated with biologics manufacturing, Selexis has developed modules based on next generation sequencing (NGS) methods for the comprehensive genetic characterization, clonality assessment and authentication of manufacturing cell lines.
Selexis believes in the promise of these newer biologics and have committed significant resources to ensure their technologies can meet the new expression challenges that these non-natural proteins present.